Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 2,377 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Visual Function Clear all
Completed Not applicable Interventional

The eyeGuide: Improving Glaucoma Self-management With a Personalized Behavior Change Program

NCT03159247
View directory record Official record
Conditions
Medication Adherence, Glaucoma
Interventions
eyeGuide
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
40 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 23, 2026, 8:24 AM EDT
Recruiting Not applicable Interventional

Developing Evidence-Based Cognitive Approaches to Improve Adjustment to Vision Loss

NCT07073521
View directory record Official record
Conditions
Depression, Anxiety, Visual Impairment, Adjustment, Adjustment Disorder With Anxious Mood, Adjustment Disorder With Depressed Mood, Blindness, Acquired, Blindness and Low Vision, Vision Loss
Interventions
Integrated Cognitive Behavioral Therapy (CBT) & Mindfulness Group Intervention for Adjustment to Vision Loss
Behavioral
Lead sponsor
The Chicago Lighthouse
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 23, 2026, 8:24 AM EDT
Completed No phase listed Observational

Screening for Research Subjects With Anterior Segment Diseases

NCT00088348
View directory record Official record
Conditions
Eye Diseases
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Not applicable Interventional Results available

Pilot Study of TENS for Ocular Pain

NCT05531643
View directory record Official record
Conditions
Eye Pain
Interventions
High frequency forehead TENS, Low frequency forehead TENS
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 23, 2026, 8:24 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

NCT06883123
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
Prairie Eye Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tactile Low Vision Labeling of Ophthalmic Drops

NCT04483882
View directory record Official record
Conditions
Low Vision Aids
Interventions
Tactile Labels for Drug identity and dose frequency
Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 100 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Not applicable Interventional Results available

Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)

NCT00382824
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Coenzyme Q10, Placebo
Dietary Supplement · Other
Lead sponsor
Lahey Clinic
Other
Eligibility
30 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
3
States / cities
Birmingham, Alabama • Boston, Massachusetts • Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety of USB005 in Healthy Volunteers

NCT03615196
View directory record Official record
Conditions
Healthy Volunteers
Interventions
USB005 (aclerastide) Ophthalmic Solution, USB005 Ophthalmic Solution Placebo
Drug
Lead sponsor
US Biotest, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Oct 23, 2026, 8:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Examination of Balance, Vestibular, and Ocular Functions and Activity Following Concussion

NCT02317107
View directory record Official record
Conditions
Brain Concussion
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
12 Years to 40 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

NCT03070392
View directory record Official record
Conditions
Uveal Melanoma
Interventions
IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Biological · Drug
Lead sponsor
Immunocore Ltd
Industry
Eligibility
18 Years to 99 Years
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
23
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

NCT01528111
View directory record Official record
Conditions
Primary Open-angle Glaucoma, Ocular Hypertension
Interventions
LX7101 (0.125%), LX7101 (0.25%), LX7101 Vehicle
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
5
States / cities
Morrow, Georgia • Memphis, Tennessee • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2015 · Synced Oct 23, 2026, 8:24 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma

NCT03712904
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Stereotactic Body Radiation Therapy, Ziv-Aflibercept
Radiation · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 23, 2026, 8:24 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Apremilast in the Treatment of Uveitis

NCT00889421
View directory record Official record
Conditions
Uveitis
Interventions
Apremilast
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Phase 3 Interventional Results available

DE-117 Spectrum 5 Study

NCT03697811
View directory record Official record
Conditions
Primary Open-angle Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
32
States / cities
Chandler, Arizona • Glendale, California • Mission Hills, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 23, 2026, 8:24 AM EDT
Terminated Not applicable Interventional Results available

Reliability and Reproducibility of the Eye Check Tonometer

NCT04639947
View directory record Official record
Conditions
Glaucoma, Glaucoma, Suspect
Interventions
EyeCheck, Traditional Tonometer (Goldmann and Tonopen)
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

ACCURATE Study for Subjects With Dry Eyes

NCT04237012
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Dextenza 0.4Mg Intracanalicular Insert, Over the counter Artificial tears
Drug · Other
Lead sponsor
The Eye Centers of Racine and Kenosha
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Racine, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 23, 2026, 8:24 AM EDT
Active, not recruiting Phase 2 Interventional

Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma

NCT04577300
View directory record Official record
Conditions
Glaucoma
Interventions
NT-501, Sham comparator
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure

NCT01173471
View directory record Official record
Conditions
Raised Intraocular Pressure
Interventions
AZD4017, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
7
States / cities
Newport Beach, California • Atlanta, Georgia • Morrow, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 23, 2026, 8:24 AM EDT
Enrolling by invitation Not applicable Interventional

Evaluation of a Scalable Educational Intervention for Adjustment and Coping to Vision Loss

NCT07715695
View directory record Official record
Conditions
Visual Loss
Interventions
audiovisual educational intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 89 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 8:24 AM EDT
Completed No phase listed Observational

Effect of Controlled Adverse Environment (CAE) on Tear Film Stability

NCT01547936
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)

NCT00698945
View directory record Official record
Conditions
Ocular Hypertension, Open-Angle Glaucoma
Interventions
Istalol and Optive, Alphagan
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Petaluma, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2008 · Synced Oct 23, 2026, 8:24 AM EDT
Terminated No phase listed Observational

Evaluation of Ocular Lens Proteins in Cataract From Individuals With Down Syndrome

NCT03778528
View directory record Official record
Conditions
Cataract, Down Syndrome
Interventions
cataract surgery
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Month to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Phase 4 Interventional Results available

Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

NCT05207865
View directory record Official record
Conditions
Migraine, Episodic Migraine, Phonophobia, Photophobia
Interventions
Rimegepant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
19
States / cities
Phoenix, Arizona • Hawthorne, California • North Hollywood, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 23, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies

NCT04622345
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
VSJ-110, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 23, 2026, 8:24 AM EDT